These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations. Bardia A; Gounder M; Rodon J; Janku F; Lolkema MP; Stephenson JJ; Bedard PL; Schuler M; Sessa C; LoRusso P; Thomas M; Maacke H; Evans H; Sun Y; Tan DSW Oncologist; 2020 Jan; 25(1):e160-e169. PubMed ID: 31395751 [TBL] [Abstract][Full Text] [Related]
3. Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies. Borthakur G; Popplewell L; Boyiadzis M; Foran J; Platzbecker U; Vey N; Walter RB; Olin R; Raza A; Giagounidis A; Al-Kali A; Jabbour E; Kadia T; Garcia-Manero G; Bauman JW; Wu Y; Liu Y; Schramek D; Cox DS; Wissel P; Kantarjian H Cancer; 2016 Jun; 122(12):1871-9. PubMed ID: 26990290 [TBL] [Abstract][Full Text] [Related]
4. A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors. Watanabe K; Otsu S; Hirashima Y; Morinaga R; Nishikawa K; Hisamatsu Y; Shimokata T; Inada-Inoue M; Shibata T; Takeuchi H; Watanabe T; Tokushige K; Maacke H; Shiaro K; Ando Y Cancer Chemother Pharmacol; 2016 Jun; 77(6):1157-64. PubMed ID: 27071922 [TBL] [Abstract][Full Text] [Related]
5. Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. Jain N; Curran E; Iyengar NM; Diaz-Flores E; Kunnavakkam R; Popplewell L; Kirschbaum MH; Karrison T; Erba HP; Green M; Poire X; Koval G; Shannon K; Reddy PL; Joseph L; Atallah EL; Dy P; Thomas SP; Smith SE; Doyle LA; Stadler WM; Larson RA; Stock W; Odenike O Clin Cancer Res; 2014 Jan; 20(2):490-8. PubMed ID: 24178622 [TBL] [Abstract][Full Text] [Related]
6. Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer. Finn RS; Ahn DH; Javle MM; Tan BR; Weekes CD; Bendell JC; Patnaik A; Khan GN; Laheru D; Chavira R; Christy-Bittel J; Barrett E; Sawyer MB; Bekaii-Saab TS Invest New Drugs; 2018 Dec; 36(6):1037-1043. PubMed ID: 29785570 [TBL] [Abstract][Full Text] [Related]
7. Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II Study. Ragon BK; Odenike O; Baer MR; Stock W; Borthakur G; Patel K; Han L; Chen H; Ma H; Joseph L; Zhao Y; Baggerly K; Konopleva M; Jain N Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):431-440.e13. PubMed ID: 31056348 [TBL] [Abstract][Full Text] [Related]
8. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. Woodfield SE; Zhang L; Scorsone KA; Liu Y; Zage PE BMC Cancer; 2016 Mar; 16():172. PubMed ID: 26925841 [TBL] [Abstract][Full Text] [Related]
9. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Dummer R; Schadendorf D; Ascierto PA; Arance A; Dutriaux C; Di Giacomo AM; Rutkowski P; Del Vecchio M; Gutzmer R; Mandala M; Thomas L; Demidov L; Garbe C; Hogg D; Liszkay G; Queirolo P; Wasserman E; Ford J; Weill M; Sirulnik LA; Jehl V; Bozón V; Long GV; Flaherty K Lancet Oncol; 2017 Apr; 18(4):435-445. PubMed ID: 28284557 [TBL] [Abstract][Full Text] [Related]
10. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097 [TBL] [Abstract][Full Text] [Related]
11. Binimetinib for the treatment of NRAS-mutant melanoma. Queirolo P; Spagnolo F Expert Rev Anticancer Ther; 2017 Nov; 17(11):985-990. PubMed ID: 28851243 [TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. Perl AE; Altman JK; Cortes J; Smith C; Litzow M; Baer MR; Claxton D; Erba HP; Gill S; Goldberg S; Jurcic JG; Larson RA; Liu C; Ritchie E; Schiller G; Spira AI; Strickland SA; Tibes R; Ustun C; Wang ES; Stuart R; Röllig C; Neubauer A; Martinelli G; Bahceci E; Levis M Lancet Oncol; 2017 Aug; 18(8):1061-1075. PubMed ID: 28645776 [TBL] [Abstract][Full Text] [Related]
13. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941 [TBL] [Abstract][Full Text] [Related]
15. Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study. Kim JW; Lee KH; Kim JW; Suh KJ; Nam AR; Bang JH; Bang YJ; Oh DY Br J Cancer; 2019 Aug; 121(4):332-339. PubMed ID: 31312030 [TBL] [Abstract][Full Text] [Related]
16. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia. Navada SC; Fruchtman SM; Odchimar-Reissig R; Demakos EP; Petrone ME; Zbyszewski PS; Holland JF; Silverman LR Leuk Res; 2018 Jan; 64():10-16. PubMed ID: 29144985 [TBL] [Abstract][Full Text] [Related]
17. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor. Bendell JC; Javle M; Bekaii-Saab TS; Finn RS; Wainberg ZA; Laheru DA; Weekes CD; Tan BR; Khan GN; Zalupski MM; Infante JR; Jones S; Papadopoulos KP; Tolcher AW; Chavira RE; Christy-Bittel JL; Barrett E; Patnaik A Br J Cancer; 2017 Feb; 116(5):575-583. PubMed ID: 28152546 [TBL] [Abstract][Full Text] [Related]
18. Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway. Sakakibara K; Tsujioka T; Kida JI; Kurozumi N; Nakahara T; Suemori SI; Kitanaka A; Arao Y; Tohyama K Int J Hematol; 2019 Aug; 110(2):213-227. PubMed ID: 31129802 [TBL] [Abstract][Full Text] [Related]
19. Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia. O'Brien MM; Alonzo TA; Cooper TM; Levine JE; Brown PA; Slone T; August KJ; Benettaib B; Biserna N; Poon J; Patturajan M; Chen N; Simcock M; Zimmerman L; Kolb EA Pediatr Blood Cancer; 2021 Jul; 68(7):e28946. PubMed ID: 33694257 [TBL] [Abstract][Full Text] [Related]
20. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]